Trevena, Inc. to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

On February 22, 2021, Trevena, Inc. (TRVN) announced a corporate update presentation at the 10th Annual SVB Leerink Global Healthcare Conference.

The event is scheduled for February 26, 2021, at 8:40 a.m. EST, featuring Bob Yoder, Senior VP and Chief Commercial Officer.

The webcast will be accessible on Trevena's Investors section. The company focuses on CNS disorders, with one approved product, OLINVYK™, and several investigational drug candidates, including TRV250 for migraine and TRV734 for opioid use disorder.

CHESTERBROOK, Pa., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will present a corporate update at the 10^th Annual SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8:40 a.m. EST.

Presentation Details
Date:	Friday, February 26, 2021
Time:	8:40 a.m. Eastern Time
Presenter:	Bob Yoder, Senior Vice President and Chief Commercial Officer
Webcast:	https://wsw.com/webcast/svbleerink47/trvn/2707456

A link to the webcast will be available on the Events page of the Investors section on the Company’s website at www.trevena.com/investors/events-presentations/ir-calendar.

About Trevena

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the U.S., OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.

For more information, please visit www.Trevena.com.

Investor Contact:
Daniel Ferry
LifeSci Advisors
Phone: 617-430-7576
Email: IR@trevena.com

Company Contact:
Bob Yoder, SVP and Chief Commercial Officer
Trevena, Inc.
Phone: 610-354-8840

FAQ

When is Trevena's next corporate update presentation?

Trevena's next corporate update presentation is on February 26, 2021, at 8:40 a.m. EST.

Who will present at the SVB Leerink Conference for Trevena?

Bob Yoder, the Senior VP and Chief Commercial Officer, will present at the conference.

Where can I access the Trevena conference webcast?

The Trevena conference webcast can be accessed via their Investors section on their website.

What is Trevena, Inc. focused on?

Trevena, Inc. focuses on developing and commercializing novel medicines for central nervous system disorders.

What approved product does Trevena have?

Trevena has one approved product, OLINVYK™ (oliceridine) injection, for managing acute pain.